Fortrea

Fortrea Holdings Inc.
Type	Public
Traded as	Nasdaq: FTRE; S&P 600 component;
Industry	Pharmaceutical industry
Founded	1968 as Environmental Sciences Corporation; 1996 as Covance; January 31, 2023 as Fortrea
Headquarters	Durham, North Carolina, U.S.; operations in over 90 countries
Key people	Anshul Thakral, President, CEO, Chairman; Jill McConnell, CFO;
Services	Contract research organization
Revenue	US$2.723 billion (2025);
Operating income	-US$872 million (2025);
Net income	-US$986 million (2025);
Total assets	US$2.715 billion (2025);
Total equity	US$563 million (2025);
Number of employees	Approximately 14,300 (2025)
Website	fortrea.com
	Footnotes;

Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in approximately 100 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.

Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2024, it conducted more than 5,930 clinical trials involving over 1 million subjects, as well as over 500 studies for medical device companies.

The company is one of the largest participants in the international primate trade and is engaged in animal testing, most specifically animal testing on non-human primates.

The company traces its roots to Environmental Sciences Corporation, formed in 1968. It was known as Hazleton from 1972 to 1990, Corning Lab Services from 1990 to 1996, Covance from 1996 to 2021, and Labcorp Drug Development from 2021 to 2023.

The company is ranked 992nd on the Fortune 1000 (76th in the healthcare sector).